RLMD
RLMD
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$1.67M
Insider Sales
0
$0
Total Volume
$1.67M
6 transactions
Net Activity
+$1.67M
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
- •High accumulation: total purchase value exceeds $1M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
P - Purchase Insiders
$978.35B total
Quick Actions
RLMD has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at RLMD (RLMD) engaged in a total of 6 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $1.67M.
The net insider activity for RLMD shows a net buying bias of $1.67M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 788.3K shares valued at $394.17B on Nov 5, 2025.
$RLMD stock is down 17% today. Here's what we see in our data.
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
RLMD - Relmada Therapeutics Inc Stock Price and Quote
RLMD Forecast — Price Target — Prediction for 2027
Relmada's planned Nov. 12 webcast will cover quarterly results and business progress.
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
FAQs About RLMD Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for RLMD.